Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune cell activity while anti-VEGF augments intra-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Wallin, Jeffrey J., Bendell, Johanna C., Funke, Roel, Sznol, Mario, Korski, Konstanty, Jones, Suzanne, Hernandez, Genevive, Mier, James, He, Xian, Hodi, F. Stephen, Denker, Mitchell, Leveque, Vincent, Cañamero, Marta, Babitski, Galina, Koeppen, Hartmut, Ziai, James, Sharma, Neeraj, Gaire, Fabien, Chen, Daniel S., Waterkamp, Daniel, Hegde, Priti S., McDermott, David F.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013615/
https://ncbi.nlm.nih.gov/pubmed/27571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12624
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars